Background
 Under resource-limited circumstances, standard clinical practice for prioritized illnesses and conditions were introduced to nurses and midwives in primary health care (PHC) facilities in Timor-Leste. This research aims to asses the use of medicines and standard treatment guidelines (STGs) in community health centers (CHCs) in Timor-Leste and to analyze factors that influence adherence to STGs.
Methods
 Randomly sampled 20 CHCs without beds were visited from February to August, 2006. In each CHC, 100 retrospective samples from patient registration books and 30 prospective observations were collected and then quantitatively analyzed. Open-ended interviews to three members of health personnel per CHC were qualitatively analyzed.
Results
 Use of injections in Timor-Leste was extremely low when compared to results from other countries that used the same international indicators. The percentage of encounters with an antibiotic prescribed was significantly lower for prescribers with clinical nurse training than those without the training. A significantly higher level of prescribing adherence was observed among clinical nurse prescribers. None of the facility characteristics investigated was associated with the CHC's overall prescribing adherence to STGs. Open-ended interviews to CHC health personnel revealed that changes brought about by the introduction of STGs were positively perceived by respondents, especially clinical nurses.
Discussion
 Unlike previous studies on physician adherence to STGs in western countries, changes brought about by the introduction of STGs were positively perceived by PHC health personnel in Timor-Leste. STGs were developed and introduced in a policy framework that reflected local needs and reality and related with the Basic Package of Health Services policy and other policies and programs, such as human resource development, medicines policy and resource allocation plans. That fact was considered to have produced positive results in this study. Timor-Leste's experience implies a potential of STGs for non-physician health personnel working at PHC level in other resource-limited areas.

Objective: To evaluate efficacy and toxicity of a novel orally active bidentate iron chelator, 1-(N-acetyl-6-aminohexyl)-3-hydroxy-2-methylpyridin-4-one (CM1) in mice under normal and iron overload conditions. Methods: Wild type C57BL/6 mice were fed with normal and 0.2% (w/w) ferrocene-supplemented (Fe) diets, respectively for 240 d and orally given the CM1 (50, 100 and 200 mg/kg) for 180 d. Blood iron profiles, hematological indices, liver enzymes and histopathology were determined. Results: CM1 treatment lowered plasma levels of labile plasma iron and non-transferrin bound iron, but not ferritin in the Fe-fed mice. However, the treatment did not impact blood hemoglobin level, white blood cell and platelet numbers in both normal diet and Fe diet-fed mice. Interestingly, CM1 treatment did not markedly elevate plasma aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase activities in the normal diet-fed mice but it tended to increase the levels of the liver enzymes slightly in the Fe-fed mice. Hematoxylin and eosin staining result showed no abnormal pathological changes in heart, liver and spleen tissues. Conclusions: It is clear that CM1 would not be toxic to bone marrow and liver cells under normal and iron-overload conditions.